ResMed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh
RMD: XASX (AUS)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| A$76.00 | Dyvbzzl | Rgznlwwbl |
ResMed Mask and Accessories Resupply Fuels a FVE Upgrade Despite Coronavirus Impacting Near Term
Business Strategy and Outlook
ResMed is taking a “smart devices” and “big data” approach to further entrench itself as one of the two leading players in the global sleep apnea market. The strategy is two-fold – accelerating diagnosis of the underpenetrated market and monitoring patient compliance which keeps diagnosed patients in the treatment net and payors happier to reimburse the cost of respiratory devices.